NHS England agrees deal for gene therapy for spinal muscular atrophy
NHS England has agreed a deal to ensure that Zolgensma (onasemnogene abeparvovec), a one-off gene therapy medicine, will be made available for patients with spinal muscular atrophy.The drug, labelled…
Read Original Article: NHS England agrees deal for gene therapy for spinal muscular atrophy »
